Cohance Lifesciences Ltd. NSE: COHANCE | BSE: 543064

Cohance Lifesciences Ltd. Live Share Price Today, Share Analysis and Chart

Name: Cohance Lifesciences Ltd.: Is Infosys Ltd. worth buying?
Item: Cohance Lifesciences Ltd.
Rating: 2.020708375
Author: Trendlyne DVM scores

Expensive Performer

about

Incorporated in 2018, Suven Pharmaceuticals is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Specialty Chemicals and formulated drugs under contract...

1055.20 23.95 (2.32%)

29.46% Gain from 52W Low

97,295

NSE+BSE Volume

NSE 15 Jul, 2025 10:04 AM (IST)

Loading... You have run out of DVM views! Check usage

Subscribe now to see details

Medium Financial Strength

50.0 / 100

Expensive Valuation

22.7 / 100

Technically Neutral

39.0 / 100

Expensive Performer These stocks are with medium quality and mid-range technical aspects. However, their financials make them little expensive so choose the right moment to buy them. View Similar Embed DVM

1,313

1Yr Price target upside is 24%

6 analysts

Cohance Lifesciences Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

VOTE: Is Suven Pharmaceuticals Ltd. worth buying?

25 Votes:

Buy 68.0%

Sell 12.0%

Hold 20.0%

Cohance Lifesciences Ltd. Live Share Price Today, Share Analysis and Chart

Incorporated in 2018, Suven Pharmaceuticals is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Specialty Chemicals and formulated drugs under contract...

29.46% Gain from 52W Low

SWOT Analysis

Cohance Lifesciences Live Price Chart